drugset / Trial / NCT05434156
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
RandomizedSequentialTriple-blindTreatment
Summary
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
Timeline
- Start
- 2022-10-27
- Primary completion
- 2025-12
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ELE-101 | Unknown | 0.25 mg | Intravenous |
| Subject | ELE-101 | Unknown | 0.75 mg | Intravenous |
| Subject | ELE-101 | Unknown | 2 mg | Intravenous |